AlphAIAlphAI — Financial news for AI agents
stocktitan.netOCT 232 min read$MGNX

Tumors shrank in 6 of 22 patients with head and neck cancer; 2 responses to the experimental drug were unconfirmed.

MacroGenics (MGNX) reported positive interim Phase 1 data for MGC026, its B7-H3-directed antibody-drug conjugate, showing a 27% overall response rate in 22 heavily pretreated SCCHN patients. The drug demonstrated manageable safety and tolerability. The company plans to initiate a front-line SCCHN cohort evaluating MGC026 in combination with pembrolizumab in early 2027. Data were presented at the ESMO 2026 Congress.

Original reporting
stocktitan.net
Published Oct 23, 2026, 1:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 1:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$MGNX
Bullish
high confidence
Mentioned
$MGNX
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$MGNXBullishMed
01

Why it matters

The interim results provide a tangible efficacy signal for MGC026, supporting its planned front‑line combination with pembrolizumab.

02

Market read

First‑report of Phase 1 data for a listed biotech; potential catalyst for stock movement.

03

What to watch

The trial size is small and safety data, while encouraging, remain limited.

Relevance 8/10Novelty 8/10Timing: today

Background

MacroGenics presented the data at the ESMO 2026 Congress in Madrid.

Company-level read

Ticker impact

$MGNXBullishHigh confidence
Context

MacroGenics announced positive Phase 1 interim data for MGC026 with a 27% response rate in head and neck cancer patients.

Expected impact

likely upside as the data validates the ADC's activity and safety profile

Evidence & confidence

Phase 1 data for a biotech can move the stock sharply, especially with confirmed responses and a clear development path.

Market effects

Sector

strengthens the B7‑H3 ADC space and may boost peer biotech valuations

Regional

U.S. biotech sector could see modest buying pressure

Global

limited to biotech investors; no broad market effect

Counterpoint

What could challenge this read

Phase 1 data are early; investors may wait for Phase 2 before committing.

Key entities

  • company
    MacroGenics, Inc.

    Clinical‑stage biopharma developing antibody‑drug conjugates.

  • drug_candidate
    MGC026

    B7‑H3‑directed ADC targeting solid tumors.

Read at source← All news

Related articles

OCT 23
$MGNXMedAI 8/10

MacroGenics reports phase 1 data for MGC026 in solid tumors

MacroGenics Inc. (MGNX) reported phase 1 trial data for MGC026, an antibody-drug conjugate targeting B7-H3, in advanced solid tumors. 85 patients were enrolled, with 29% response rate in dose-escalation and 27% in head and neck cancer cohort. Grade 3+ adverse events occurred in 51% of patients, with no grade 5 events. The company plans further trials with pembrolizumab in 2027.

investing.com2 min
AUG 13
$MGNXMed

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

MACROGENICS INC (MGNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position • Announced sale of manufacturing operations (July 2026) for $122.5 million and transition to fully outsourced model with leaner, approximately

SEC EDGAR 8-K6 min
AUG 11
$MGNXMed

MacroGenics stock rises on $10M Gilead option exercise

MacroGenics (NASDAQ:MGNX) shares rose 4.3% after hours after Gilead Sciences exercised an option on a preclinical bispecific program under their 2022 collaboration, triggering a $10 million payment. Gilead holds an exclusive license using MacroGenics’ TRIDENT platform targeting two undisclosed solid tumor targets. MacroGenics may receive up to about $1.6 billion more in milestones and royalties.

investing.com2 min
JUL 7
$MGNXMed

MACROGENICS INC (MGNX): Completion of Acquisition or Disposition of Assets

MACROGENICS INC (MGNX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-99.2 3 exhibit99-2proforma.htm EX-99.2 Document Exhibit 99.2 MACROGENICS, INC. UNAUDITED CONSOLIDATED PRO FORMA FINANCIAL INFORMATION Effective as of June 30, 2026, MacroGenics, Inc. (the “Company”) completed the previously announced sale (the “Closing”) of certain assets and

SEC EDGAR 8-K4 min
JUL 2
$MGNXMedAI 8/10

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations – LiveNews.co.nz

Bora Pharmaceuticals (TWSE:6472; OTCQX:BORAY) said it completed its acquisition of MacroGenics’ Rockville, Maryland GMP biologics drug-substance facility and a Frederick warehousing center for $122.5m via Bora Biologics USA. Bora also signed a long-term CDMO service agreement with MacroGenics. Bora Biologics now has 20,000L SUB capacity across US sites and Taiwan.

livenews.co.nz3 min